Takeda Announces NATPARA Special Use Program in the U.S.

  • Sep 2019

In the wake of the recall of hypoparathyroidism drug NATPARA, the drug’s manufacturer, Takeda, is working with the FDA to develop a Special Use Program.

The program is intended to support patients previously prescribed NATPARA who are facing life-threatening complications as a result of discontinuation of NATPARA.

Through this program, healthcare providers will be able to request NATPARA for these extraordinary, life-threatening cases.  It is anticipated that an extremely small number of patients prescribed NATPARA will qualify for this very limited program. Additional information for healthcare providers about the Special Use Program can be found here.  Patients who have questions about their eligibility under the Special Use Program or about their individual treatment plans should consult with their healthcare providers.

In a release, Takeda stated that while this program is an important first step, it will only help a very small number of patients.  “We recognize that many more patients are in need of NATPARA to control their hypoparathyroidism.  Takeda continues to work with the FDA on both short- and long-term solutions to bring NATPARA back to the broader patient community, which remains our highest priority,” according to the statement.

“We are committed to the hypoparathyroidism community and the safe supply of NATPARA.  We will continue to work urgently on this issue and keep patients and healthcare providers informed of our progress in resuming supply,” the statement adds.

On September 18, the Endocrine Society issued a joint statement with the American Society for Bone Mineral Research (ASBMR) to assist healthcare providers who may be treating patients prescribed NATPARA.

You may also like

  • Low Socioeconomic Status Raises Pregnant Women’s Risk of Exposure to Thyroid-Disrupting Chemicals

    Exposure to some endocrine-disrupting chemicals (EDCs) that harm the thyroid gland has increased over the past 20 years among U.S. women of childbearing age and pregnant women, especially among those with lower social and economic status, according to a study presented at ENDO 2024. The researchers focused this study on women who may be particularly…

  • TED Patients Report Maintained Improvement 2 Years After Teprotumumab Infusions

    Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly two years later, according to industry-supported research being presented Sunday at ENDO 2024 in Boston, Mass., and published in the journal Thyroid. “Thyroid eye disease is a lifelong autoimmune disease that can worsen or flare, regardless of how it has been treated….

Find more in